Impact Biomedicines' Acquisition

Impact Biomedicines was acquired by Celgene on January 08, 2018.

Impact Biomedicines is developing treatments for patients with complex cancers. The company's pipeline is centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhi…

Articles about Impact Biomedicines' Acquisition: